Seer, Inc.

NASDAQ•SEER

CEO: Dr. Omid C. Farokhzad M.D., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2020-12-04

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

連絡先情報

3800 Bridge Parkway, Suite 102, Redwood City, CA, 94065, United States

650-453-0000

seer.bio

時価総額

$102.12M

PER (TTM)

-1.4

17.9

配当利回り

52週高値

$2.41

52週安値

$1.62

52週レンジ

24%

順位54Top 78.1%

2.7

F-Score

改良版 Piotroski 分析

7年ファンダメンタル

弱い • 2.7 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2019-2025

財務ダッシュボード

Q4 2025 データ

売上高

$4.20M+0.00%

直近4四半期の推移

EPS

-$0.29+0.00%

直近4四半期の推移

フリーCF

-$11.10M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Total Revenue Increased 17% Total revenue reached $16.6M in 2025, up 17% ($2.4M increase), driven by higher product sales and service revenue.

Gross Profit and Loss Improvement Gross profit grew 20% to $8.5M; Net loss improved 15% to $(73.6M), reflecting reduced operating expenses.

Operating Expenses Significantly Reduced Total operating expenses decreased 19% to $86.5M, primarily due to 25% reduction in SG&A expenses ($14.0M decrease).

Proteograph ONE Throughput Gains Third-generation Proteograph ONE assay launched in May 2025, delivering 3.6x throughput increase over previous assay versions.

リスク要因

Continued Operating Losses Expected Company has incurred significant losses since 2017; expects to continue incurring net losses and negative cash flows near term.

Market Acceptance Uncertainty Commercial success hinges on broad scientific and market acceptance of Proteograph, which may take longer than anticipated.

Intellectual Property Enforcement Risk Reliance on patents; challenges or failure to enforce IP rights could allow competitors to commercialize similar products.

Reliance on Key Customers Related party revenue was 5% of total revenue in 2025; loss of key customers could materially impact financial results.

見通し

Drive Installed Base Utilization Focus on driving higher utilization and consumable pull-through from the rapidly expanding installed base across all customer types.

Expand Population-Scale Cohorts Announced several population-scale studies in 2025; actively discussing expansion with additional key biobanks globally.

Leadership in AI Biology Platform Pursue strategic ecosystem partnerships to establish leadership as preferred proteomic data platform for AI-driven discovery.

New Product Innovation Focus Aim to continuously innovate and develop new products, applications, and analysis tools across the R&D value chain.

同業比較

売上高 (TTM)

GLUE

$181.54M

+1112.3%

NRIX

$83.98M

+54.0%

KYMR

$39.20M

-16.7%

粗利益率 (最新四半期)

KYMR

2763.6%

-2680.7pp

FHTX

91.3%

-245.3pp

CCCC

83.6%

+13.4pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
KYMR	$6.45B	-21.4	-29.1%	4.7%
PHVS	$1.65B	-8.3	-67.1%	0.2%
NRIX	$1.30B	-5.4	-57.5%	8.1%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

-0.0%

横ばい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月11日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし